Phosphorus

Results from a newly published study indicate that an adaptive nutritional and educational intervention may effectively stabilize serum phosphorus levels in adults receiving hemodialysis.

AUSTIN, Texas — Dietitians treating patients on dialysis identified the phosphorus recommendation from the 2020 Kidney Disease Outcome Quality Initiative difficult to implement among other recommendations, a presenter said.

Treating patients with chronic kidney disease and hyperkalemia with patiromer reduced serum phosphorus and serum potassium levels during a 2-week period, according to data published in the American Journal of Kidney Diseases.

Shivam Joshi, MD, knows he has few options for his patients on dialysis when it comes to the management of hyperphosphatemia. And none are very effective.

Researchers created a new metric among patients on dialysis according to the ratio between phosphorous and normalized protein catabolic rate that correlates with their survival.

Plant-based diets may be a helpful strategy for patients on dialysis to lower their phosphorous levels, according to a speaker at the virtual Annual Dialysis Conference.

Data from a single-center, cross-sectional study showed medications commonly prescribed to patients with chronic kidney disease were low in inorganic phosphorus, with most phosphorus coming from excipients.

While acknowledging the “substantial evidence” presented by Ardelyx Inc. in its new drug application for tenapanor, the FDA said in a letter to the pharmaceutical company that the phosphorus control drug lacked “clinical significance.”

Pharmaceutical company Ardelyx Inc. saw a 70% drop in its stock value on Monday after announcing that the FDA had “identified deficiencies” in the company’s new drug application for its serum phosphorus drug tenapanor.

Sucroferric oxyhydroxide treatment in patients on hemodialysis resulted in improved serum phosphorus control, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.